Inspira Technologies OXY B.H.N. (IINN) Expected to Announce Earnings on Wednesday

Inspira Technologies OXY B.H.N. (NASDAQ:IINN) is anticipated to post its results before the market opens on Wednesday, April 1st. Analysts expect Inspira Technologies OXY B.H.N. to post earnings of ($0.20) per share and revenue of $0.20 million for the quarter.

Inspira Technologies OXY B.H.N. Trading Up 1.0%

Shares of IINN opened at $0.40 on Tuesday. Inspira Technologies OXY B.H.N. has a 1 year low of $0.34 and a 1 year high of $1.65. The company has a current ratio of 1.56, a quick ratio of 1.30 and a debt-to-equity ratio of 0.08. The stock has a 50-day simple moving average of $0.62 and a 200-day simple moving average of $0.90.

Institutional Trading of Inspira Technologies OXY B.H.N.

A hedge fund recently bought a new stake in Inspira Technologies OXY B.H.N. stock. Citadel Advisors LLC acquired a new stake in Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 82,567 shares of the company’s stock, valued at approximately $105,000. Citadel Advisors LLC owned about 0.65% of Inspira Technologies OXY B.H.N. as of its most recent filing with the Securities and Exchange Commission. 12.72% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inspira Technologies OXY B.H.N. in a report on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $2.00.

Inspira Technologies OXY B.H.N. Company Profile

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels.